-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In a previous analysis of the RATIONALE-304 (NCT03663205) trial, tislelizumab (TIS) plus platinum-based chemotherapy significantly improved clinical outcomes over chemotherapy alone in treatment-resistant advanced nsq- NSCLC (by IRC).
In a previous analysis of the RATIONALE-304 (NCT03663205) trial, tislelizumab (TIS) plus platinum-based chemotherapy significantly improved clinical outcomes over chemotherapy alone in treatment-resistant advanced nsq- NSCLC (by IRC).
Recently, the RATIONALE-304 study, led by Shanghai Chest Hospital, reported at AACR biomarker analysis of baseline tissue and blood TMB (tTMB and bTMB, respectively)
Patients with nsq-NSCLC were randomly assigned in a 2:1 ratio to TIS+platinum+pemetrexed or platinum+pemetrexed
Patients with nsq-NSCLC were randomly assigned in a 2:1 ratio to TIS+platinum+pemetrexed or platinum+pemetrexed
RESULTS: Of the 325 RATIONALE-304-treated patients without EGFR sensitizing mutations, 177 (54.
The relationship between TMB and TIS + chemotherapy and PFS benefit of chemotherapy
Taken together, in this retrospective analysis, neither tTMB nor bTMB was significantly associated with PFS benefit, suggesting that tTMB and bTMB have limited clinical utility in the setting of TIS+chemotherapy as first-line treatment for advanced nsq-NSCLC
Taken together, in this retrospective analysis, neither tTMB nor bTMB was significantly associated with PFS benefit, suggesting that tTMB and bTMB have limited clinical utility in the setting of TIS+chemotherapy as first-line treatment for advanced nsq-NSCLC
source:
source:https://#!/10517/presentation/19967
https://#!/10517/presentation/19967 https://#!/10517/presentation/19967Leave a comment here